Clinical trialNCT02454933CompletedPhase 3Interventional

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

SponsorAstraZenecaEnrollment29Locally Advanced or Metastatic EGFR T790M+ NSCLC

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in patients with Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M mutation-positive Non-Small Cell Lung Cancer who have received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

James CH Yang, MD
National Taiwan University Hospital
Principal Investigator
clinicaltrials.gov ↗
Leora Horn, MD
Vanderbilt University, Nashville, USA
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Research Site
Toronto, Ontario, Canada

South Korea

Research Site
Busan, South Korea
Research Site
Daegu, South Korea
Research Site
Incheon, South Korea
Research Site
Jinju, South Korea
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Ulsan, South Korea

Taiwan

Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taipei, Taiwan

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AZD9291MEDI4736

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Jul 2015
Primary completion: 21 Aug 2017
Completion: 21 Jun 2023
Last update posted: 19 Sept 2024
Registered enrollment: 29
Registry id: NCT02454933

Cross-registrations

EU-CTR / CTIS (EudraCT)2015-001858-15

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.